1. "Jedd Wolchok"
  2. "Body Imaging Service"
Formats
  1. Journal Article (12)
  2. Meeting Abstract (7)
Groups
  1. Body Imaging Service (19)
  2. Department of Medicine (19)
  3. GSK Faculty (19)
  4. Melanoma and Immunotherapeutics Service (19)
  5. Radiology, Department of (19)
  6. Solid Tumor Oncology Division (19)

More Groups

People
  1. Jedd Wolchok (19)
  2. Paul Chapman (11)
  3. Katherine Panageas (10)
  4. Mark Bluth (9)
  5. Richard Carvajal (9)
  6. Gary Schwartz (8)

More People

Years
  1. 2023 (1)
  2. 2019 (2)
  3. 2018 (4)
  4. 2017 (1)
  5. 2015 (1)
  6. 2014 (3)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Clinical Cancer Research (2)
  3. JAMA - Journal of the American Medical Association (2)
  4. Cancer (1)
  5. Cancer Cell (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (4)
  3. American Medical Association (2)
  4. Cell Press (1)
  5. Lippincott Williams & Wilkins (1)
  6. Oxford University Press (1)

More Publishers

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
    Journal Article

    Pai, J. A.; Hellmann, M. D.; Sauter, J. L.; Mattar, M.; Rizvi, H.; Woo, H. J.; Shah, N.; Nguyen, E. M.; Uddin, F. Z.; Quintanal-Villalonga, A.; more...
    Cancer Cell (2023)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma
    Journal Article

    Skoulidis, F.; Goldberg, M. E.; Greenawalt, D. M.; Hellmann, M. D.; Awad, M. M.; Gainor, J. F.; Schrock, A. B.; Hartmaier, R. J.; Trabucco, S. E.; Gay, L.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
    Journal Article

    Teo, M. Y.; Seier, K.; Ostrovnaya, I.; Regazzi, A. M.; Kania, B. E.; Moran, M. M.; Cipolla, C. K.; Bluth, M. J.; Chaim, J.; Al-Ahmadie, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing
    Journal Article

    Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J. L.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Robust antitumor responses result from local chemotherapy and CTLA-4 blockade
    Journal Article

    Ariyan, C. E.; Brady, M. S.; Siegelbaum, R. H.; Hu, J.; Bello, D. M.; Rand, J.; Fisher, C.; Lefkowitz, R. A.; Panageas, K. S.; Pulitzer, M.; more...
    Cancer Immunology Research (2018)

    Fulltext@MSK | Save
  • Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma
    Journal Article

    Shoushtari, A. N.; Bluth, M. J.; Goldman, D. A.; Bitas, C.; Lefkowitz, R. A.; Postow, M. A.; Munhoz, R. R.; Buchar, G.; Hester, R. H.; Romero, J. A.; more...
    Melanoma Research (2017)

    Fulltext@MSK | Save
  • Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition
    Journal Article

    Carvajal, R. D.; Lawrence, D. P.; Weber, J. S.; Gajewski, T. F.; Gonzalez, R.; Lutzky, J.; O'Day, S. J.; Hamid, O.; Wolchok, J. D.; Chapman, P. B.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma
    Meeting Abstract

    Bitas, C.; Shoushtari, A. N.; Bluth, M. J.; Bhuchar, G.; Hester, R. H.; Romero, J.; Fitzpatrick, L.; Lefkowitz, R. A.; Panageas, K.; Schwartz, G. K.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save